Eli Lilly buys psychedelic nasal spray access in a $2.8B deal with FDA Breakthrough status
Lilly is paying $2.8 billion for a DMT-based treatment-resistant depression nasal spray, fast-tracked by the FDA.
By Turki Al-Mutairi·· 3 min
Loading the Newsroom
Curating from trusted global sources…